RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

BeOne gets rights to RevMed’s 4 RAS inhibitors in Asia; MoonLake’s sonelokimab hits Ph3 PsA goals; Avere raises $500M; Novo-AWS AI hub; Sobi pays $75M for Innate lacutamab deal.Read More